Panagiotis from Cyprus

Registered at the short selling broker Pepperstone, 3 minutes ago.

» Try Pepperstone you too
78.6% of retail investor accounts lose money when trading spread bets and CFDs with Pepperstone.
Don't show again

Novartis AG (NVS) shares information

Novartis AG – ADR

24h Change

0.16 %


Live rate: Market closed

Stock data per Wednesday 14 Apr, 2021

0.14 (+ 0.16%)
US Market is closed

Live Stock price in graph for Novartis AG – ADR (NVS)

  • Latest Volume

    1,701,466 (-7.97 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    86.89 USD

  • Today low

    86.46 USD

  • 52 week high

    94.72 USD

  • 52 week low

    74.07 USD

  • YTD Change


Quick links


Latest news about Novartis AG – ADR

Below you can find the most recent news posts about Novartis AG – ADR, primarily from US and UK based news sources.

Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio

Wednesday, 7 April 2021, 13:08:04
Novartis AG (NYSE: NVS ) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets. During the three-year collaboration, Artios and Novartis will … Full story available on
— Benzinga

Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know

Monday, 29 March 2021, 17:16:06
A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU ), valuing the company at $1.2 billion. A $375 million PIPE on the SPAC merger includes investments from SoftBank Group Corp (OTC: SFTBY ), T. Rowe Price, Illumina, Inc. (NASDAQ: ILMN ), Novartis AG (NYSE: NVS ) and accounts advised by Ark Invest. Kevin Conroy, the CEO of EXACT Sciences Corporation (NASDAQ: EXAS ) will join the board of directors after the merger is complete. Current shareholders of CM Life Sciences II will own 14% of the company after the merger. PIPE investors will own 20% of the company after the merger. About SomaLogic: Using … Full story available on
— Benzinga

Novartis corrects chairman's comments about kickbacks case

Wednesday, 24 March 2021, 16:30:28

Novartis’ $2B cancer drug spurs ‘groundbreaking’ PhIII data for prostate cancer

Tuesday, 23 March 2021, 14:11:17
Continuing a streak of upbeat announcements on its radioligand portfolio, Novartis says that their Phase III study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients — setting up a likely approval some analysts believe would be worth more than a billion
— Endpoints News

Autoinjectors Market Is Expected To Exhibit 18.1% CAGR By 2027 | Novartis AG, SHL Medical, Eli Lilly and Company

Tuesday, 23 March 2021, 13:54:31
Rise in anaphylaxis cases and increases in R&D activities by key players in the market are anticipated to drive the market. Rapid growth has been observed in adoption of biosimilars over branded drugs, which provides low cost treatment options for
— OpenPR

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: offer a large number of stocks for trading. Register an account today and check if they have NVS available or trade one of the many other CFD stocks they have.
Risk warning: 71.2% of retail investor accounts lose money when trading CFDs with Capital.